June 22 (Bloomberg) -- GlaxoSmithKline Plc’s experimental diabetes medicine albiglutide lowered blood sugar better than Merck & Co.’s Januvia or Sanofi’s Amaryl, while more patients reported gastrointestinal side effects, in a study.
About 10 percent of patients taking albiglutide reported nausea, compared with 7 percent of those taking Januvia and 6 percent on Amaryl, according to an summary of the 104-week study dubbed Harmony 3 to be presented tomorrow at the American Diabetes Association’s annual meeting in Chicago. Vomiting and diarrhea were also more frequent among those taking albiglutide, the abstract said. All patients took the drugs with metformin.
The findings add to mixed results released so far by Glaxo, which has conducted eight late-stage studies on albiglutide. Analysts have said the Glaxo drug may be able to differentiate itself from other diabetes drugs on its side effects profile even after it failed to help diabetics control their blood sugar as well as Novo Nordisk A/S’s Victoza in another trial.
Albiglutide’s once-weekly dosing would make the drug more convenient for patients compared with existing once-daily treatments. Still, it will face challenges as it enters a “crowded area,” Patrick Vallance, Glaxo’s head of pharmaceuticals research and development, said in an interview.
Glaxo submitted albiglutide to U.S. regulators in January and to European regulators in March. The company has said it’s seeking a partner to help market the drug.
It’s unlikely that sales of albiglutide will reach levels of Avandia, which was once the world’s best-selling diabetes pill with peak annual sales of of about $3 billion for Glaxo. That drug was withdrawn from the market in Europe in 2010 and sales were limited in the U.S. because of an increased risk of heart attacks.
Sales of albiglutide may reach $301 million in 2016, according to the average of nine analysts’ estimates compiled by Bloomberg.
To contact the reporter on this story: Makiko Kitamura in London at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com